News

Filter

Current filters:

Noven Pharmaceuticals

Noven's Brisdelle is first non-hormonal treatment for menopausal hot flashes to be approved by FDA

01-07-2013

The US Food and Drug Administration on Friday (June 28) approved Noven Pharmaceuticals' Brisdelle (paroxetine)…

BrisdelleHisamitsu PharmaNorth AmericaNoven PharmaceuticalsparoxetinePharmaceuticalRegulationWomen's Health

US FDA warns pregnant women to not use valproate migraine prevention medicines

07-05-2013

The US Food and Drug Administration is alerting health care providers and patients that medications including…

Abbott LaboratoriesGenericsNeurologicalNorth AmericaNoven PharmaceuticalsPharmaceuticalRegulationSanofivalproate Sodium Injection

Noven files NDA for non-hormonal therapy for menopausal vasomotor symptoms

30-08-2012

USA-based Noven Pharmaceuticals, a wholly-owned subsidiary of Japanese drugmaker Hisamitsu Pharmaceuticals…

Hisamitsu PharmaNorth AmericaNoven PharmaceuticalsPharmaceuticalRegulationWomen's Health

Shire divests ADHD drug Daytrana to Noven Pharma; says 2010 earnings outlook unchanged

11-08-2010

Dublin, Ireland-based specialty biopharmaceutical company Shire is divesting global rights to its Daytrana…

DaytranaFinancialLicensingNeurologicalNoven PharmaceuticalsPharmaceuticalShire

COMPANY SPOTLIGHT

Menarini

Back to top